CARE (Combating Antibiotic Resistance Enterobacteriaceae
Patients with positive cultures for CRE (Cabapenem-Resistant Enterobacteriaceae) will be treated with either plazomicin or colistin (both with added meropenem or tigecycline) for up to 4 days. The study is looking to see if plazomicin is as good or better than the current treatment for CRE.
Who may be Eligible
Ages 18-15; Positive culture for CRE; Not pregnant or breast feeding; Not have study defined prohibited co-infections; Not have antibiotic therapy for more than 72 hours prior to start; Not be on study disallowed mdications.